Nephrotoxic Risk Associated With Combination Therapy of Vancomycin and Piperacillin-Tazobactam in Critically Ill Patients With Chronic Kidney Disease

被引:0
|
作者
Pipkin, Tamyah [1 ,7 ]
Pope, Stuart [2 ,8 ]
Killian, Alley [1 ]
Green, Sarah [1 ]
Albrecht, Benjamin [1 ]
Nugent, Katherine [3 ,4 ,5 ,6 ]
机构
[1] Emory Univ Hosp, Dept Pharm, Atlanta, GA USA
[2] Emory Univ Hosp Midtown, Dept Pharm, Atlanta, GA USA
[3] Emory Univ, Dept Med, Sch Med, Atlanta, GA USA
[4] Emory Univ, Dept Emergency Med, Sch Med, Atlanta, GA USA
[5] Emory Univ, Dept Anesthesiol, Sch Med, Atlanta, GA USA
[6] Emory Univ, Div Crit Care Med, Sch Med, Atlanta, GA USA
[7] Norton Womens & Childrens Hosp, Dept Pharm, 4001 Dutchmans Ln, Louisville, KY 40207 USA
[8] Emory Univ Hosp Midtown, Dept Pharm, 550 Peachtree St NE, Atlanta, GA 30308 USA
关键词
acute kidney injury; vancomycin; piperacillin-tazobactam; chronic kidney disease; nephrotoxicity; INJURY;
D O I
10.1177/08850666241234577
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The combination of vancomycin and piperacillin-tazobactam (VPT) has been associated with acute kidney injury (AKI) in hospitalized patients when compared to similar combinations. Additional studies examining this nephrotoxic risk in critically ill patients have not consistently demonstrated the aforementioned association. Furthermore, patients with baseline renal dysfunction have been excluded from almost all of these studies, creating a need to examine the risk in this patient population. Methods: This was a retrospective cohort analysis of critically ill adults with baseline chronic kidney disease (CKD) who received vancomycin plus an anti-pseudomonal beta-lactam at Emory University Hospital. The primary outcome was incidence of AKI. Secondary outcomes included stage of AKI, time to development of AKI, time to return to baseline renal function, new requirement for renal replacement therapy, intensive care unit and hospital length of stay, and in-hospital mortality. Results: A total of 109 patients were included. There was no difference observed in the primary outcome between the VPT (50%) and comparator (58%) group (P = .4), stage 2 or 3 AKI (15.9% vs 6%; P = .98), time to AKI development (1.7 vs 2 days; P = .5), time to return to baseline renal function (4 vs 3 days; P = .2), new requirement for RRT (4.5% vs 1.5%; P = .3), ICU length of stay (7.3 vs 7.4 days; P = .9), hospital length of stay (19.3 vs 20.1 days; P = .87), or in-hospital mortality (15.9% vs 10.8%; P = .4). A significant difference was observed in the duration of antibiotic exposure (3.32 vs 2.62 days; P = .045 days). Conclusion: VPT was not associated with an increased risk of AKI or adverse renal outcomes. Our findings suggest that the use of this antibiotic combination should not be avoided in this patient population. More robust prospective studies are warranted to confirm these findings.
引用
收藏
页码:860 / 865
页数:6
相关论文
共 50 条
  • [41] The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock
    Sun, Yang
    Liu, Yu
    Wang, Jixia
    Cui, Can
    HELIYON, 2023, 9 (06)
  • [42] Incidence of Acute Kidney Injury (AKI) in Critically Ill Patients Receiving Concomitant Vancomycin with Piperacillin-Tazobactam or Cefepime; a Systemic Review and Meta-analysis
    Alaradi, Lamees
    Albariqi, Nada
    Alanazi, Mona
    Alghassab, Naif
    Aseri, Tief
    Alahmadi, Lujain
    Alahmadi, Ahmad
    Althobaiti, Aseel
    Alqarafi, Yousef
    Bokhari, Habeeba
    Qutob, Rayan A.
    Almaimani, Mohanad
    JOURNAL OF INTENSIVE CARE MEDICINE, 2025,
  • [43] Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients
    Buhlinger, Kaitlyn M.
    Fuller, Kathryn A.
    Faircloth, Cassidy B.
    Wallace, Jessica R.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (16) : 1204 - 1210
  • [44] Risk and Time-to-Onset of Acute Kidney Injury With Vancomycin Plus Piperacillin-tazobactam Combination: Analysis Using JADER
    Ide, Naohito
    Sako, Ken-Ichi
    Takigawa, Masaki
    Tanaka, Hiroyuki
    IN VIVO, 2024, 38 (03): : 1436 - 1442
  • [45] Nut Cracked? Does the ACORN Trial End the Debate Surrounding Vancomycin and Piperacillin-Tazobactam Combination Therapy and Increased Risk for Acute Kidney Injury?
    Pogue, Jason M.
    Aitken, Samuel L.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (01):
  • [46] Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients
    LeCleir, Lisa K.
    Pettit, Rebecca S.
    PEDIATRIC PULMONOLOGY, 2017, 52 (08) : 1000 - 1005
  • [47] Evaluation of the Risk of Acute Kidney Injury (AKI) Associated With Vancomycin Plus Piperacillin-Tazobactam (VPT) Compared With Vancomycin Plus Cefepime (VC)
    Jeon, Nakyung
    Staley, Ben
    Klinker, Kenneth P.
    Ghandi, Aakash B.
    Winterstein, Almut G.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 270 - 270
  • [48] CLINICAL IMPACT OF HIGH-DOSE PIPERACILLIN-TAZOBACTAM FOR PNEUMONIA IN CRITICALLY ILL OBESE PATIENTS
    Tran, Christina
    Crotty, Matthew
    Akins, Ronda
    CRITICAL CARE MEDICINE, 2020, 48
  • [49] PIPERACILLIN-TAZOBACTAM VERSUS CEFEPIME INCIDENCE OF ACUTE KIDNEY INJURY IN COMBINATION WITH VANCOMYCIN AND TOBRAMYCIN IN PEDIATRIC CYSTIC FIBROSIS PATIENTS
    LeCleir, L. K.
    Pettit, R. S.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 325 - 325
  • [50] Pharmacokinetics of extended-infusion piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Hebert, Elisabeth
    Beauchamp, Annie
    Lavigne, Viviane
    Munoz, Danya
    Awissi, Don K.
    Savoie, Michel
    Lebrun, Genevieve
    Fagnan, Mylene
    Robitaille, Robert
    Amyot, Julie
    Tetreault, Nicolas
    Lavallee, Christian
    Varin, France
    Pichette, Vincent
    Leblanc, Martine
    PHARMACOTHERAPY, 2014, 34 (06): : E78 - E79